Hypoxia‐Responsive Prodrug of ATR Inhibitor, AZD6738, Selectively Eradicates Treatment‐Resistant Cancer Cells
Abstract Targeted therapy remains the future of anti‐cancer drug development, owing to the lack of specificity of current treatments which lead to damage in healthy normal tissues. ATR inhibitors have in recent times demonstrated promising clinical potential, and are currently being evaluated in the...
Сохранить в:
| Главные авторы: | , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Wiley
2024-09-01
|
| Серии: | Advanced Science |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/advs.202403831 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|